Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes

Lingvay, Ildiko; Legendre, Jaime L.; Kaloyanova, Polina F.; Zhang, Song; Adams-Huet, Beverley; Raskin, Philip
October 2009
Diabetes Care;Oct2009, Vol. 32 Issue 10, p1789
Academic Journal
OBJECTIVE -- Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL). RESEARCH DESIGN AND METHODS-- In treatment-naive patients with newly diagnosed type 2 diabetes, insulin and metformin were initiated for a 3-month lead-in period, then patients were randomly assigned to insulin and metformin (insulin group) or metformin, pioglitazone, and glyburide (oral group) for 36 months. Hypoglycemic events, compliance, A1C, weight, QoL, and treatment satisfaction were assessed. RESULTS-- Of 29 patients randomly assigned into each group, 83% (insulin group) and 72% (oral group) completed this 3-year study. At study completion, A1C was 6.1 ± 0.6% (insulin group) versus 6.0 ± 0.8% (oral group). Weight increased similarly in both groups (P = 0.09) by 4.47 kg (95% CI 0.89-8.04 kg) (insulin group) and 7.15 kg (95% CI 4.18-10.13 kg) (orals group). Hypoglycemic events did not differ between groups (mild 0.51 event/person-month in the insulin group vs. 0.68 event/person-month in the orals group, P = 0.18 and severe 0.04 event/person-year in the insulin group vs. 0.09 event/person-year in the orals group, P = 0.53). Compliance, QoL, and treatment satisfaction were similar between groups, with 100% of patients randomly assigned to insulin willing to continue such treatment. CONCLUSIONS-- When compared with a clinically equivalent treatment regimen, insulin-based therapy is effective and did not cause greater weight gain or hypoglycemia nor decrease compliance, treatment satisfaction, or QoL. Insulin is safe, well-accepted, and effective for ongoing treatment of patients with newly diagnosed type 2 diabetes.


Related Articles

  • Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Riddle, Matthew; Pencek, Richard; Charenkavanich, Supoat; Lutz, Karen; Wilhelm, Ken; Porter, Lisa // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1577 

    OBJECTIVE -- To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS -- In a 24-week open-label, multicenter study, 113 patients were randomly...

  • THE THERAPEUTIC EFFECTS OF BIPHASIC INSULIN ASPART ON PATIENTS WITH DIABETES TYPE 2. Mujanović-Narančić, Alma // Medical Journal;abr-jun2011, Vol. 17 Issue 2, p113 

    Diabetes mellitus is a chronic and cureless disease but with an adequate treatment it can significantly improve the quality of life and extend the life expectancy. Within the treatment of Diabetes mellitus type 2 the therapy with biphasic insulin is accepted. The aims of this research are the...

  • Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Young, Jason R.; McAdam-Marx, Carrie // Clinical Medicine Insights: Endocrinology & Diabetes;2010, Issue 3, p65 

    Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin detemir has generally but not consistently...

  • Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diamant, Michaela; Nauck, Michael A.; Shaginian, Rimma; Malone, James K.; Cleall, Simon; Reaney, Matthew; de Vries, Danielle; Hoogwerf, Byron J.; MacConell, Leigh; Wolffenbuttel, Bruce H. R. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2763 

    OBJECTIVE Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is associated with weight gain and hypoglycemia. This study compared the efficacy and safety of exenatide twice daily or mealtime insulin...

  • Starting Insulin Treatment for Diabetes. Jin, Jill // JAMA: Journal of the American Medical Association;6/11/2014, Vol. 311 Issue 22, p2347 

    The article discusses insulin treatment for diabetes. Topics covered include the importance of insulin in the treatment of type 2 diabetes, the reasons patients do not want to start insulin treatment, and some of the things about insulin that doctors might discuss with their patients, including...

  • Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Home, Philip D.; Chunduo Shen; Hasan, Mohammad I.; Latif, Zafar A.; Jian-Wen Chen; González Gálvez, Guillermo // Diabetes Care;May2014, Vol. 37 Issue 5, p1237 

    OBJECTIVE Individualization of therapy choices requires the prediction of likely response. Predictor and explanatory factors of change in HbA1c were studied using data from a large observational study of starting insulin analog therapy (the A1chieve study). RESEARCH DESIGN AND METHODS Univariate...

  • Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain. Hollmand, R. R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p77 

    STUDY DESIGN Design: randomised controlled trial (Treating to Target in Type 2 Diabetes [4-T]). Allocation: concealed. Blinding: unblinded. STUDY QUESTION Setting: 58 centres in Ireland and the UK. Patients: 708 patients ⩾18 years of age (mean age 62 y, 64% men) who had type 2 diabetes for...

  • Efficacy of once-daily insulin.  // Primary Care Reports;Dec2009 Pharmacology Watch Supp, p1 

    The article discusses a new study on the use of once-a-day insulin to treat type 2 diabetes. The study was conducted by researchers from England, involving 708 patient who had suboptimal hemoglobin A1c. It was found that the basal insulin group presented lesser hypoglycemic episodes as well as...

  • Intensive Insulin Therapy in Type 2 Diabetes (T2D) Patients Previously Treated with Glargine Plus Oral Agents: Prandial NPL/Lispro Mixtures vs Glargine/Lispro Basal/Bolus. Rosenstock, Julio; Ahmann, Andrew J.; Colon, Gildred; Scism-Bacon, Jamie L.; Jiang, Honghua H.; Martin, Sherry // Diabetes;Jun2007 Supplement 1, Vol. 56, pA51 

    We report the first head-to-head comparison of intensive insulin therapies (intensive mixtures therapy [IMT] vs basal bolus therapy [BBT]) in T2D patients previously treated with glargine (≥30 U/d) + oral agents. Patients with A1C ≥ 7.5 and ≤ 12% were randomized to IMT (lispro...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics